ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance

During the past decade, more than 10 targetable oncogenic driver genes have been validated in non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Ye, Mingxiang, Zhang, Xinxin, Li, Nan, Zhang, Yong, Jing, Pengyu, Chang, Ning, Wu, Jianxiong, Ren, Xinling, Zhang, Jian
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4914285/
https://ncbi.nlm.nih.gov/pubmed/26802023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6935
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires